Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus carboplatin-based chemotherapy in first-line metastatic squamous NSCLC
jRCT2080222847Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: overall survival and progression-free survival. Started May 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222847.